Bibliographical noteFunding Information:
Author Affiliations: Department of Neurology, Amsterdam Neuroscience, Amsterdam MS Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands (van Kempen, Strijbis, Al, Uitdehaag, Killestein); Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands (Steenhuis, Rispens). Accepted for Publication: March 19, 2021. Published Online: April 30, 2021. doi:10.1001/jamaneurol.2021.1364 Corresponding Author: Zoé L. E. van Kempen, PhD, Department of Neurology, Amsterdam Neuroscience, Amsterdam MS Center, Amsterdam University Medical Centers, Vrije Universiteit, De Boelelaan 1118, 1081 HV Amsterdam, the Netherlands (email@example.com). Author Contributions: Drs van Kempen and Killestein had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: van Kempen, Strijbis, Rispens, Killestein. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: van Kempen. Critical revision of the manuscript for important intellectual content: Strijbis, Al, Steenhuis, Uitdehaag, Rispens, Killestein. Statistical analysis: van Kempen, Strijbis. Obtained funding: van Kempen, Killestein. Administrative, technical, or material support: van Kempen, Strijbis, Al, Steenhuis. Supervision: Uitdehaag, Rispens, Killestein. Conflict of Interest Disclosures: Dr van Kempen reports a grant from Dutch MS Research Foundation (grant 20-005 PP) during the conduct of the study. Dr Uitdehaag reports personal fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, and Teva consultancy fees outside the submitted work. Dr Rispens reports grants from Netherlands Organisation for Health Research and Development (ZonMw) during the conduct of the study. Dr Killestein reports a grant from Dutch MS Research Foundation (grant 20-005 PP) during the conduct of the study; personal fees from Biogen, Genzyme, Merck, Novartis, and Roche; and grants from Teva, Biogen, Genzyme, Merck, Novartis, and Roche, outside the submitted work. No other disclosures were reported. Funding/Support: We are very grateful to the Dutch MS Research Foundation for fully funding this study (grant 20-005 PP). Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank the patients for participating in this study. Furthermore, we thank Birgit Lissenberg-Witte, PhD, Amsterdam UMC, for statistical contributions; Gert-Jan Wolbink, PhD, Amsterdam Rheumatology and Immunology Center, Jean-Luc Murk, PhD, Elizabeth Tweesteden Hospital, and Floor Loonstra, MD, Amsterdam UMC, for help in the study design; Samantha Noteboom, MSc, Brigit de Jong, PhD, and Bob van Oosten, PhD, Amsterdam UMC, for help with data collection; and Gerard van Mierlo, MSc, and Rivka de Jongh, MSc, Sanquin Research, for performing SARS-CoV-2 antibody testing. This study is affiliated with the Dutch Target to B! Consortium on COVID-19 in Autoimmune Diseases (www.target-to-b.nl). We acknowledge the support of our colleagues in the Dutch Target to B! Consortium on COVID-19 in Autoimmune Diseases: Filip Eftimov, PhD, Taco Kuijpers, PhD, Luuk Wieske, PhD, Sander Tas, PhD, and Koos van Dam, MD, Amsterdam UMC; Marieke van Ham, PhD, Sanquin Research; and Laura Boekel, MD, Rheumatology and Immunology Center. These individuals were not compensated.
Copyright 2021 Elsevier B.V., All rights reserved.